INTRODUCTION
============

In most hemodialysis (HD) patients blood pressure at the end of HD (postHD) is below starting levels (preHD). This peridialytic blood pressure decline is attributed to fluid and salt removal \[[@gfx309-B1]\]. However, in some patients, postHD blood pressure is regularly increased above preHD levels \[[@gfx309-B2], [@gfx309-B3]\]. This phenomenon---termed intradialytic hypertension (iHTN)---is recurrent and persistent in a subset of maintenance HD patients. While there is currently no universally accepted definition of iHTN, most authors use a peridialytic rise of systolic blood pressure (SBP) of ≥10 mmHg as a threshold \[[@gfx309-B4], [@gfx309-B5]\]. Cohort studies showed an iHTN prevalence of 8--13% \[[@gfx309-B2], [@gfx309-B4]\]. iHTN patients have an increased risk for hospitalizations and mortality compared with those whose blood pressure decreases during HD \[[@gfx309-B4], [@gfx309-B5]\]. Park *et al.* \[[@gfx309-B6]\] reported in a large cohort study that both a 30 mmHg peridialytic SBP decrease and any peridialytic SBP rise were associated with increased mortality rates \[[@gfx309-B6]\]. This emphasizes the risks associated with iHTN and the clinical need to identify the underlying mechanisms and develop preventive interventions.

While the iHTN pathophysiology is not yet fully understood and likely multifactorial, observational studies noticed that older age, lower body weight, lower serum creatinine and albumin levels, as well as the use of more antihypertensive medication are associated with peridialytic SBP increase \[[@gfx309-B4], [@gfx309-B5]\]. Additionally, an association between dialysate-to-serum sodium gradient and intradialytic change of SBP has been observed \[[@gfx309-B7]\], indicating a role of diffusive intradialytic sodium gain in the development of iHTN. Other proposed mechanisms are an activation of the sympathetic nervous system \[[@gfx309-B8]\], stimulation of the renin--angiotensin--aldosterone system (RAAS), increased endothelin-1 secretion, dialytic removal of antihypertensive drugs and variations in potassium or ionized calcium blood levels \[[@gfx309-B9]\]. The potential pathophysiologic pathways of iHTN and treatment options have been reviewed recently \[[@gfx309-B10], [@gfx309-B11]\].

In a recent study we found that 10% of chronic HD patients had arterial oxygen saturation (SaO~2~) \<90% for more than one-third of their treatment time, which was associated with increased hospitalization and mortality rates \[[@gfx309-B12]\]. Fluid overload, impaired respiratory function and ventilation--perfusion mismatch are potential causes of intradialytic hypoxemia \[[@gfx309-B13]\]. Of note, intradialytic hypoxemia may stimulate sympathetic activation \[[@gfx309-B14], [@gfx309-B15]\]. Given these strands of evidence we set out to test the hypothesis of an inverse association between peridialytic SBP change and intradialytic SaO~2~ in the aforementioned HD cohort where concurrent measurements of both peridialytic SBP and intradialytic SaO~2~ were available.

MATERIALS AND METHODS
=====================

Population and study design
---------------------------

We conducted this retrospective study in a recently reported cohort of chronic HD patients from 17 US facilities of the Renal Research Institute (RRI) \[[@gfx309-B12]\]. Records between January 2012 and September 2014 were reviewed. A 6-month observation period was defined on a patient level, which started on the date of a patient's first HD with both SaO~2~ and SBP measurements. Only patients with arteriovenous access and at least 10 HD treatments with eligible SaO~2~ measurements were included in the analysis. Patients were treated with bicarbonate dialysate and polysulfone membranes. Patients were censored in the event of kidney transplantation, dialysis modality change, transfer to outside of RRI or recovery of kidney function. The study was conducted in accordance with the Helsinki Declaration and was approved by the New England Institutional Review Board (\#14-446), which waived the need for informed consent.

Measurement of oxygen saturation
--------------------------------

We measured the intradialytic SaO~2~ as reported recently \[[@gfx309-B12]\] using the Crit-Line Monitor (CLM) (Fresenius Medical Care North America, Waltham, MA, USA), which is approved by the US Food and Drug Administration for the measurement of hematocrit and oxygen saturation in the extracorporeal circuit. The CLM reports oxygen saturation 1× per minute. The manufacturer-reported accuracy of SaO~2~ measurement is 2%. CLM data were automatically transferred to the RRI data warehouse and subsequently to the study database. The use of CLM is standard care in RRI clinics, albeit with some utilization variability related to the phased device rollout 2012--14. CLM values with the following characteristics were deemed implausible or unreliable and hence excluded: relative blood volume (RBV) \>102%; SaO~2~ \>100%; hematocrit levels ≤15% or \>55%; and data points that were collected after the end of the prescribed treatment time. In the absence of acceptable data during \>50% of the treatment time, the entire HD session was excluded. Likewise, the entire treatment was excluded if the rate of change of RBV was \>5 percentage points compared with values 10 min and 5 min earlier on one or more occasion, if SaO~2~ of 50% was recorded more than 40 times or the mean intradialytic SaO~2~ was ≤80%, a level indicative of venous rather than arterial blood.

Measurement of blood pressure
-----------------------------

Across all RRI clinics the staff pay particular attention to the methodology of blood pressure measurement and follow a standardized protocol, where blood pressure is obtained by an automated device integrated in the HD machine on the non-access arm with the patient seated in the dialysis chair. For this research we used SBP measurements that were taken shortly before and after HD.

Clinical and laboratory data
----------------------------

Laboratory measurements (Spectra Laboratories, Rockleigh, NJ, USA) were downloaded to the RRI data warehouse and extracted to the study database.

Comorbidities
-------------

Congestive heart failure (CHF), diabetes and chronic obstructive pulmonary disease (COPD) were defined using International Classification of Diseases, Ninth Revision (ICD-9) codes.

Statistical analysis
--------------------

Descriptive statistics comprised mean (± standard deviation) for continuous variables and percentages for categorical variables. SaO~2~- and SBP-related variables were calculated first per HD treatment, then per patient and finally per group. To avoid potential interference with priming and rinsing procedures, Start SaO~2~ was defined as the mean SaO~2~ between treatment time 5 and 20 min, and End SaO~2~ as the mean SaO~2~ between the final 20 and 5 min.

Peridialytic SBP change was calculated as postHD SBP -- preHD SBP. In line with current literature we defined iHTN as a peridialytic SBP increase ≥10 mmHg and persistent iHTN (piHTN) as average peridialytic SBP increase ≥10 mmHg throughout the entire 6-month observation period. Patients were stratified based on the presence or absence of piHTN. We compared characteristics of piHTN and non-piHTN patients by computing mean group differences with 95% confidence intervals (95% CI).

Using linear mixed effects (LME) models we also explored on a continuous scale the association between peridialytic SBP change and mean intradialytic SaO~2~ or the fraction (%) of treatment time spent with a SaO~2~ ≤90%. Here, the peridialytic SBP change was the outcome variable and SaO~2~ indicators the exposure. Variables were calculated per patient on a treatment level. We conducted unadjusted and adjusted analyses. Confounders were selected based on their documented or hypothesized association with exposure and outcome. In the minimally adjusted model we included age, diabetes, interdialytic weight gain (IDWG) as % of postHD weight, ultrafiltration rate (UFR), preHD SBP and epoietin alfa dose as additional independent variables. The fully adjusted model included in addition race, gender and vintage.

Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA) and R i386 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS
=======

Patient characteristics
-----------------------

Out of 1532 patients with SaO~2~ measurements, 550 patients (36%) were excluded because they had \<10 HD sessions with eligible SaO~2~ recordings ([Supplementary data, Figure S1](#sup1){ref-type="supplementary-material"}). The final analytical cohort comprised 982 chronic HD patients with 29 872 HD treatments with eligible SaO~2~ measurements.

![Histogram of percentage of HD sessions with iHTN. The denominator is the number of patient-level HD treatments. The dashed line indicates the population mean. iHTN was defined as a peridialytic SBP change ≥10 mmHg.](gfx309f1){#gfx309-F1}

Detailed patient characteristics are depicted in Table [1](#gfx309-T1){ref-type="table"}. Briefly, age was 62.1 ± 15.2 years, 59.1% were male and 52.6% were white. Dialysis vintage was 3.9 ± 4.1 years, 50.7% were diabetic, 23.3% had CHF and 8.4% had COPD. Table 1Characteristics of the entire study population and after stratification into groups with and without piHTNVariablesAll patientspiHTNDifference between groups, mean (95% CI)PresentAbsentPatients, *N* (%)982 (100)53 (5.4)929 (94.6)n.a.Number of treatments with SaO~2~ measurements29 872126628 606n.a.Demographics Men, %59.145.359.9−14.6 (−29.3 to 0.2) Race, % white52.752.852.60.2 (−13.8 to 14.2) Age, years62.1 ± 15.263.9 ± 15.461.9 ± 15.21.9 (−2.4 to 6.3) Vintage, years3.9 ± 4.13.7 ± 3.83.9 ± 4.1−0.3 (−1.4 to 0.9) BMI, kg/m^2^28.7 ± 7.726.2 ± 5.728.8 ± 7.8−2.6 (−4.4 to −0.9) Obese, %35.1 ± 47.819.2 ± 39.836.0 ± 48.0−16.8 (−29.6 to −4.0) Post weight, kg82.1 ± 22.769.7 ± 17. 782.7 ± 22.8−13.0 (−14.0 to −12.0)Oxygen saturation, % Mean SaO~2~92.8 ± 2.2192.1 ± 2.5392.9 ± 2.19−0.8 (−0.9 to −0.6) % of time spent below 90% SaO~2~10.0 ± 23.517.9 ± 30.99.6 ± 23.18.3 (6.6 to 10.0) % of time spent below 87% SaO~2~2.5 ± 12.25.5 ± 18.22.4 ± 11.93.1 (2.1 to 4.1) Start SaO~2~92.8 ± 2.5292.0 ± 2.792.8 ± 2.5−0.8 (−1.0 to −0.7) End SaO~2~93.4 ± 2.3092.6 ± 2.593.4 ± 2.3−0.8 (−1.0 to −0.7)Comorbidities, % Diabetes50.760.450.210.2 (−4.3 to 24.8) CHF23.326.423.13.3 (−9.9 to 16.4) COPD8.47.58.5−1.0 (−9.3 to 7.3)Laboratory and treatment-related parameters % of treatments with iHTN per patient19.1 ± 16.561.9 ± 12.116.7 ± 13.045.2 (41.7 to 48.6) Peridialytic SBP change[^b^](#tblfn3){ref-type="table-fn"}, mmHg−10.1 ± 24.516.3 ± 22.5−11.3 ± 23.927.6 (26.3 to 28.9) PreHD SBP, mmHg146.7 ± 26.5139.2 ± 24.2147.1 ± 26.5−7.8 (−9.2 to −6.5) PostHD SBP, mmHg136.6 ± 25.0155.5 ± 25.0135.8 ± 24.719.7 (18.3 to 21.2) IDWG, kg2.3 ± 1.42.1 ± 1.42.3 ± 1.4−0.2 (−0.3 to −0.1) IDWG, % of postHD weight2.9 ± 1.63.2 ± 1.82.9 ± 1.50.3 (0.2 to 0.4) Treatment time, min203.5 ± 36.4198.9 ± 38.7203.7 ± 36.3−4.8 (−7.0 to −2.6) UFR, mL/h/kg8.2 ± 4.09.0 ± 4.88.1 ± 4.00.9 (0.6 to 1.2) Ultrafiltration volume, L2.3 ± 1.22.1 ± 1.22.3 ± 1.2−0.2 (−0.3 to −0.1) Blood flow rate, mL/min438 ± 53431 ± 59439 ± 53−8 (−11 to −5) Serum albumin, g/dL4.0 ± 0.43.9 ± 0.44.0 ± 0.3−0.1 (−0.2 to −0.1) Hgb, g/dL10.9 ± 1.310.3 ± 1.211.0 ± 1.3−0.6 (−0.8 to −0.5) WBC, 1000/μL6.5 ± 3.16.6 ± 2.56.5 ± 3.20.1 (−0.4 to 0.6) NLR3.6 ± 2.44.6 ± 4.33.6 ± 2.31.0 (0.2 to 1.9) Equilibrated Kt/V, g/kg body weight/day1.5 ± 0.41.6 ± 0.41.5 ± 0.30.1 (0.0 to 0.2) Creatinine8.9 ± 3.07.8 ± 2.89.0 ± 3.0−1.2 (−1.7 to −0.6) Dialysate sodium, mmol/L137.2 ± 0.6137.0 ± 0.4137.2 ± 0.6−0.1 (−0.2 to −0.1) Serum sodium, mmol/L138.9 ± 3.2138.4 ± 4.1139.0 ± 3.2−0.6 (−1.4 to 0.2) Sodium gradient[^c^](#tblfn4){ref-type="table-fn"}−1.8 ± 3.2−1.3 ± 4.1−1.8 ± 3.10.5 (−0.4 to 1.2) Serum potassium, mmol/L4.8 ± 0.64.7 ± 0.74.8 ± 0.6−0.1 (−0.2 to 0.1) Serum bicarbonate, mmol/L23.3 ± 2.823.2 ± 2.923.2 ± 2.80.0 (−0.5 to 0.6) PTH, pg/mL584 ± 561523 ± 458588 ± 566−65 (−181 to 51) Ferritin, ng/mL938 ± 529846 ± 479943 ± 530−97 (−263 to 70) Serum iron, μg/dL78.5 ± 33.472.2 ± 34.378.8 ± 33.3−6.6 (−13.3 to 0.1)Medication Epo dose, U per treatment2542 ± 40753900 ± 49072482 ± 40241418 (1144 to 1693) Iron dose, mg per treatment14.8 ± 32.220.7 ± 36.714.5 ± 31.96.2 (4.1 to 8.3)[^2][^3][^4][^5]

Peridialytic SBP change and intradialytic SaO~2~ characteristics
----------------------------------------------------------------

Mean preHD and postHD SBP were 146.7 ± 26.5 and 136.6 ± 25.0 mmHg, respectively. On average, SBP decreased by 10.1 ± 24.5 mmHg from preHD to postHD. Figure [1](#gfx309-F1){ref-type="fig"} displays the frequency of iHTN. On average patients had iHTN in 19.1±16.5% of their treatments.

Mean intradialytic SaO~2~ was 92.8 ± 2.2%. On average patients spent 10 ± 23.5% of their treatment time at SaO~2~ levels ≤90%.

Comparison between piHTN and non-piHTN patients
-----------------------------------------------

Fifty-three (5.7%) patients had piHTN. A comparison between piHTN and non-piHTN patients is displayed in Table [1](#gfx309-T1){ref-type="table"}. In piHTN patients, peridialytic SBP increased ≥10 mmHg in 62% of treatments. On average peridialytic SBP increased by 16.3 ± 22.5 mmHg, from preHD 139.2 ± 24.2 mmHg to postHD 155.5 ± 25.0 mmHg. In non-piHTN patients, peridialytic SBP increased ≥10 mmHg in 17% of treatments, and decreased on average by 11.3±23.9 mmHg, from preHD 147.1 ± 26.5 mmHg to postHD 135.8 ± 24.7 mmHg. piHTN patients were more likely to be female, had lower body weight and body mass index (BMI) and were less likely to be obese. Mean, Start and End SaO~2~ were lower in piHTN patients. These patients also spent a significantly higher fraction of their treatment time with a SaO~2~ \<90% and \<87%, respectively. IDWG and ultrafiltration volume were lower in piHTN patients, while IDWG and UFR normalized to postHD body weight were higher. In piHTN patients, serum albumin levels were lower and neutrophil-to-lymphocyte ratios higher. piHTN patients had lower hemoglobin levels while receiving significantly more epoetin and iron per treatment.

Correlates of peridialytic SBP change
-------------------------------------

Results from LME models are listed in Table [2](#gfx309-T2){ref-type="table"}. In the unadjusted analysis, a 1 percentage point increase in mean SaO~2~ was associated with a peridialytic SBP decrease of 0.46 mmHg SBP (P \< 0.001). A 1 percentage point increase of treatment time spent below 90% SaO~2~ was associated with a 0.03 mmHg peridialytic SBP increase (P = 0.004). These point estimates remained significant at various levels of multivariate adjustment (Table [2](#gfx309-T2){ref-type="table"}). Table 2Results of LME models relating indicators of SaO~2~ (independent variables) with peridialytic SBP change (dependent variable)UnadjustedMinimally adjusted[^a^](#tblfn5){ref-type="table-fn"}Fully adjusted[^b^](#tblfn6){ref-type="table-fn"}Coefficient (95% CI)P-valueCoefficient (95% CI)P-valueCoefficient (95% CI)P-valuePercentage of treatment time spent \<90% SaO~2~2.57 (0.81 to 4.33)0.0041.85 (0.18 to 3.53)0.031.86 (0.19 to 3.5)0.03Mean SaO~2~(%)−0.46 (−0.66 to −0.25)\<0.001−0.20 (−0.41 to 0.002)0.05−0.20 (−0.41 to 0.003)0.05[^6][^7]

DISCUSSION
==========

Our research in a large and diverse population of chronic HD patients for the first time shows an inverse association between intradialytic SaO~2~ and peridialytic blood pressure changes, iHTN and piHTN.

While observational studies reported several associations of iHTN with clinical parameters, the exact mechanisms are still not fully understood \[[@gfx309-B3], [@gfx309-B5], [@gfx309-B10], [@gfx309-B16]\]. Our study corroborates recently reported data of iHTN prevalence, where iHTN occurred in 90% of the patients at least once when observed over 6 months \[[@gfx309-B2]\].

A retrospective analysis of the dry weight reduction in hypertensive HD patients (DRIP) study revealed that dry weight probing modified the intradialytic blood pressure slope in addition to lowering the ambulatory blood pressure. Patients whose dry weight decreased the most during the study changed from flat intradialytic blood pressure slopes at baseline to steep declines at the end of the trial \[[@gfx309-B22]\]. More recently, bioimpedance measurements have demonstrated that patients with intradialytic SBP rise were fluid overloaded and had a higher extracellular-to-total body water ratio \[[@gfx309-B17], [@gfx309-B23], [@gfx309-B24]\]. Those studies concluded that reassessment of dry weight should be the initial approach in patients with increased postHD SBP. It is important to note that fluid overload may reduce alveolar oxygen diffusion, resulting in reduced SaO~2~ and tissue hypoxia. In fact, Anand *et al.* \[[@gfx309-B25]\] found a positive relationship between the slope of the RBV curve, an indirect marker of volume status, and change in SaO~2~, indicating a contribution of volume overload to hypoxemia. In our population piHTN patients had a lower IDWG and ultrafiltration volume in absolute terms, but higher if normalized to body weight; this finding is explained by their lower postHD weight. Furthermore, piHTN patients had a lower BMI and a lower fraction of obese patients.

We hypothesize that the activation of at least two pathways may result in a SBP rise in the face of low SaO~2~. First, poor SaO~2~ may result in tissue hypoxia. Evidence from both humans and rodents indicates that hypoxia triggers sympathetic activation and elevation of blood pressure \[[@gfx309-B26]\]. Peripheral chemoreflex sensitivity is particularly enhanced in patients with sleep apnea, which is highly prevalent in end-stage renal disease patients and frequently associated with hypertension \[[@gfx309-B30], [@gfx309-B31]\]. Additionally, sympathetic overactivity has been observed in patients with iHTN \[[@gfx309-B8]\]. Further, *in vitro* studies have shown that hypoxemia induces endothelin-1 secretion from endothelial cells, a process promoted by reactive oxygen species (ROS) \[[@gfx309-B32]\]. Kanagy *et al.* \[[@gfx309-B35]\] have shown in rats that intermittent hypoxemia triggered a significant increase of endothelin-1 plasma levels, causing increased mean arterial pressure \[[@gfx309-B35]\]. Another study in mice observed that endothelin-1 is a major contributor to the vascular inflammatory remodeling induced by intermittent hypoxia \[[@gfx309-B36]\]. Of note, in patients with sleep-disordered breathing, hypoxemia is associated with elevated plasma levels of endothelin-1 \[[@gfx309-B37]\] and facilitates endothelial dysfunction \[[@gfx309-B38], [@gfx309-B39]\]. Similarly, iHTN is associated with severe impairments of endothelial function with altered NO/ET-1 balance \[[@gfx309-B16], [@gfx309-B40], [@gfx309-B41]\]. It is intriguing to speculate that increased ROS production due to intradialytic hypoxemia and tissue hypoxia induces endothelin-1 secretion, consecutive vasoconstriction and eventually iHTN. Testing the hypothesis of a direct link between intradialytic hypoxia and BP changes would require simultaneous measurements of SaO~2~, sympathetic activity, blood pressure and endothelin-1 levels during HD. To the best of our knowledge this has not been done yet.

Carvedilol is suggested as treatment for patients with iHTN. Besides being an alpha- and beta-adrenoceptor antagonist, carvedilol is also a potent antioxidant. Therefore, it may act by preventing the effects caused by hypoxemia on endothelial cells. In a pilot study carvediol has been shown to reduce intradialytic blood pressure surges by targeting endothelial cell dysfunction \[[@gfx309-B42]\].

Patients with iHTN are also prone to interdialytic hypertension \[[@gfx309-B10], [@gfx309-B43]\]. It has been shown that the elevated postHD blood pressure persists for many hours \[[@gfx309-B44]\]. Similarly, dialysis-induced hypoxemia has been observed lasting for hours beyond the end of the HD session \[[@gfx309-B45]\]. Future studies with concurrent measurements of interdialytic SBP and SaO~2~ would be of great interest.

Admittedly, our study has a few limitations. First, as it is a retrospective observational study, no conclusions towards causation can be drawn. While we employed a widely used definition of iHTN based on peridialytic SBP change, a systematic prospective study of intradialytic blood pressure relative to SaO~2~ would be important. In addition, postHD SBP may have been modified by intradialytic interventions like change in UFR or fluid infusion on some occasions. Unfortunately, data regarding fluid status (e.g. by using bioimpedance), antihypertensive drugs and residual renal function are not recorded in our database; we acknowledge that this kind of data would have greatly added to our analysis. Lastly, our study is limited to patients with arteriovenous access.

In conclusion, this is the first study to report an association between low intradialytic SaO~2~ and iHTN. We hypothesize that low SaO~2~ may result in sympathetic activation and increased endothelin-1 secretion, both processes that would favor a blood pressure rise. Testing this hypothesis will require specifically designed prospective clinical studies with concurrent biochemical and physiological measurements. We believe that our results will motivate and encourage adequately equipped and trained clinical researchers to embark on specialized studies to that end, since further investigations in the pathophysiological mechanisms behind iHTN and its association with hypoxemia are clearly required.
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